CD274 and cancer: Cancer cells exploit the PD‐1/PD‐L1 pathway by overexpressing PD‐L1 to evade T‐cell recognition and suppress antitumor immunity.[3] Emerging evidence suggests that disrupting this signaling pathway through PD‐1 or PD‐L1 blockade substantially improves clinical outcomes across various cancers.[4]